reason report
bottom line deliv anoth solid quarter out-performance
-- notabl deliv first sale miss last quarter sinc
-- issu guidanc point oper sale growth
acceler full-year achiev
guidanc larg predic turnaround
medic deliveri nutrit bit back-end load
-- pressur certain item -- print increas
confid growth trajectori reason given
saw manag note stabil particularli
medic deliveri overal continu believ
long-term guidanc sale compound-annual-growth-rate still
achiev growth acceler beyond driven
solid execut turnaround medic deliveri nutrit
easier comp less meaning headwind pharma sale growth
plan breakthrough molecul launch end
includ one rel meaning new product
launch end could bring pharma sale growth
back compani long-term vision us sale
growth acceler stori remain intact given view
success execut medic deliveri nutrit
turnaround manag pharma headwind cyclo
brevibloc continu believ exit lrp long-
rang plan near top-lin growth organ
ahead overal med-tech market mid-single-digit rang
reiter op pt pt
previous rang dcf valuat deriv
base case upsid scenario supplement ev/fcf
ev/ ebitda analys estim price-to-earnings perspect
pt impli multipl ep estim
repres stabl multipl current level pe
ep also line large-cap med-tech group
continu turnaround medic deliveri nutrit sale
estim move lower reflect larger fx impact item
destock lvp large-volum parenter larg complet
exit easier comp back part sale estim
medic deliveri move higher reflect oper
growth growth acceler throughout year item
mostli concentr repres nearli bp drag
sale growth ep estim move
y/i larg driven
much lower share count guid vs
compani ramp share repurchas program
medic suppli devic
pt deriv rang
dcf valuat deriv
base case upsid scenario
supplement ev/fcf ev/
price-to-earnings lt ep growth
year price history/av daili volume mil
compani inform svb leerink llc research
revenu mm ep includ stock compens expens
pleas refer page import disclosur price chart analyst certif
rate share outperform price target ten
consecut beat rais ep quarter sinc spin oper margin alreadi track
ahead manag current long-rang plan increasingli strong free cash flow
gener believ post-spin new turnaround stori still room signific
upsid believ increment margin upsid potenti alreadi price
believ magnitud sale growth reacceler potenti free cash flow gener
still underappreci level increasingli becom strong free cash flow
gener stori free cash flow target vs
potenti upsid free cash flow view increas financi flexibl
invest busi drive even faster sale growth acceler invest inorgan
outsid opportun supplement top- bottom-lin growth
given compani solid execut to-dat steadi stream upcom new product launch
addit clari fill gener inject busi increasingli confid
continu drive upsid recent updat long-term growth margin
target believ margin expans stori alreadi least partli price
stock manag current guid oper margin
see room upsid margin ramp believ major
upsid alreadi price share level
sale perspect also see potenti upsid current top-lin growth target
compound-annual-growth-rate time-frame driven new product launch geograph
expans someth feel underappreci street pipelin biggest
driver sale growth acceler next five year expect launch
new product new product expect make total sale
ramp expect signific growth pd periton dialysi gener
inject biosurgeri core growth contributor drive top line grow
solid mid-singl digit higher
overal find bax margin expans stori compel believ investor
underappreci bax sale growth reacceler stori also compani cash-
gener capabl believ ebitda repres relev
measur valu compani vs price earn combin
discount cash flow analysi ev/ebitda ev/fcf arriv price
next month believ share trade rang
dcf valuat deriv base case upsid scenario supplement
price target arriv via ev/fcf ev/ ebitda analys estim
price-to-earnings perspect valuat impli multipl ep estim
repres stabl multipl current level pe ep
also line large-cap med-tech group
risk includ failur execut margin expans initi new product launch delay
possibl acquisit either dilut perceiv further baxter growth goal
could pressur stock
dollar million except per share data
good sold
research develop expens
revenu
consensu incom statement item includ contributor factset
consensu detail revenu item visibl alpha
consensu
compani report factset consensu visibl alpha consensu svb leerink estim
dollar million except per share data
good sold
research develop expens
revenu
consensu incom statement item includ contributor factset
consensu detail revenu item visibl alpha
consensu
compani report factset consensu visibl alpha consensu svb leerink estim
dollar million except asp
good sold
research develop expens
pre-tax incom continu oper
sg sale
 sale
oper expens sale
compani report svb leerink estim
baxter sale y/i
sale billion usd
revenu report
constant currenc basi
revenu report
constant currenc basi
revenu report
constant currenc basi
revenu report
revenu report
constant currenc basi flat
constant currenc basi
oper
revenu report
revenu report impli
constant currenc
flat sale growth report
basi constant
sale growth report
basi constant
flat report
constant currenc basi
margin expans
report constant
currenc basi oper
margin expans
bp
currenc basi
report constant
margin expans
bp
report impli
mid-point
constant currenc basi
margin expans
bp
report impli
mid-point
constant currenc basi
margin expans
bp
oper cf
ex
oper cf
cap ex
oper cf
cap ex
oper cf
ex
oper cf
ex
basi
declin constant
cyclo vs
constant
currenc basi
flat
constant
basi
digit constant
oper
high-single-digit growth
includ cyclo
digit constant
currenc basi
constant currenc
basi includ
recothrom
constant
basi
constant
oper
constant
cyclo clari
constant
currenc basi
recothrom
preveleak
constant
currenc basi
basi
constant
currenc basi
basi
constant
currenc basi
basi
constant
constant
report impli
constant currenc basi
report impli
constant currenc basi
report
adjust impact
cyclophosphamid competit
impact product exit
constant currenc basi
adjust impact
cyclophosphamid competit
impact product exit
compani report svb leerink estim
oper cf
cap ex
oper cf
ex
oper cf
cap ex
oper cf
cap ex
increas ex fx
increas ex fx
mid-singl digit
point-of-car solut pd
innov home periton dialysi pd solut system
improv patient access home dialysi new system
design produc steril pd solut use small water filtrat
devic would place patient home integr
sharesourc telehealth platform
hdx therapi enabl
hdx therapi extend rang molecul filter
blood dialysi result filtrat profil
close mimic natur kidney addit clearanc profil
hdx enabl theranova simpl perform
convent hemodialysi hd design work
hd machin allow clinic offer hdx therapi use exist
resourc elimin need special equip ad
clinic workflow requir hdf addit hdf
perform effect patient hdx therapi enabl
theranova crucial step bring benefit theranova
patient market
expect new product pipelin acceler growth
contribut busi
compani report svb leerink estim
final regulatori pathway fda on-
demand periton dialysi pd system drug-devic combo
expect start clinic trial
 januari announc enrol first
patient clinic trial
oct note market share leader
pd global even introduct poc pd
like grow market rate
octob begun enrol patient us
januari expect launch
first set use continu renal replac therapi
crrt sepsi manag protocol label expans
oxiri blood purif set add baxter multi-organ
therapi offer util prismaflex system
oxiri label expans take effect
countri europ well geographi
east africa began launch label expans
select market outsid
roll-out on-go
februari began limit launch
anticip full european launch later year
expect improv outcom convent
hemodialysi use particular dialyz get
better level clearanc certain molecul
latest technolog acut care therapi
new dialyz could chang game long-term term
hd expect provid uniqu advantag
amia integr sharesourc technolog allow
patient clinician commun back forth daili
may convert roughli patient
 expect acceler
also sharesourc technolog
compani report svb leerink estim
